Diindolylmethane (DIM) Information Resource Center References Section
Providing References for Biomedical Investigators Conducting Research on Diindolylmethane (DIM) and DIM Supplement Formulations
Diindolylmethane (DIM) Scientific Reference 4 From 2008:
Cancer Res. 2008 Mar 15;68(6):1927-34. Mammalian target of rapamycin repression by 3,3′-diindolylmethane (DIM) inhibits invasion and angiogenesis in platelet-derived growth factor-D-overexpressing PC3 cells. Kong D, Banerjee S, Huang W, Li Y, Wang Z, Kim HR, Sarkar FH.
Platelet-derived growth factor-D (PDGF-D) is a newly recognized growth factor known to regulate many cellular processes, including cell proliferation, transformation, invasion, and angiogenesis. Recent studies have shown that PDGF-D and its cognate receptor PDGFR-beta are expressed in prostate tumor tissues, suggesting that PDGF-D might play an important role in the development and progression of prostate cancer. However, the biological role of PDGF-D in tumorigenesis remains elusive. In this study, we found that PDGF-D-overexpressing PC3 cells (PC3 cells stably transfected with PDGF-D cDNA and referred to as PC3 PDGF-D) exhibited a rapid growth rate and enhanced cell invasion that was associated with the activation of mammalian target of rapamycin (mTOR) and reduced Akt activity. Rapamycin repressed mTOR activity and concomitantly resulted in the activation of Akt, which could attenuate the therapeutic effects of mTOR inhibitors. In contrast, Diindolylmethane (DIM) significantly inhibited both mTOR and Akt in
PC3 PDGF-D cells, which were correlated with decreased cell proliferation and invasion. Moreover, conditioned medium from PC3 PDGF-D cells significantly increased the tube formation of human umbilical vein endothelial cells, which was inhibited by DIM treatment concomitant with reduced full-length and active form of PDGF-D. Our results suggest that DIM could serve as a novel and efficient chemopreventive and/or therapeutic agent by inactivation of both mTOR and Akt activity in PDGF-D-overexpressing prostate cancer.